Pfizer made a business decision to end a Phase 2 trial for an autoimmune drug program, leaving the asset’s future uncertain. The trial tested PF-06835375 in primary immune thrombocytopenia, with the federal clinical trials listing noting the phase stop amid unresolved downstream plans. For biotech partners and investors, program discontinuations at Phase 2 often reshape competitive positioning in autoimmune pipelines, especially where mechanisms can overlap with antibody and Fc-mediated strategies. The immediate impact is the removal of near-term confirmatory data generation and a renewed need to reassign development resources. The broader signal for the sector is how development timelines can be re-priced by commercial assumptions as much as by clinical readouts.